
Lipoprotein apheresis affects lipoprotein particle subclasses more efficiently compared to the PCSK9 inhibitor evolocumab, a pilot study
Keywords: ذرات لیپوپروتئین; LDL&HIPHEN; Cholesterol; Lipoprotein particles; Lipoprotein apheresis; PCSK9-inhibition;